Novartis AG (NVS)

86.14
0.85 0.98
NYSE : Health Technology
Prev Close 86.99
Open 86.65
Day Low/High 86.07 / 87.03
52 Wk Low/High 74.97 / 96.31
Volume 1.13M
Avg Volume 1.87M
Exchange NYSE
Shares Outstanding 2.55B
Market Cap 224.37B
EPS 5.50
P/E Ratio 16.66
Div & Yield 1.84 (2.06%)

The More Things Change…

… and market internals are seeing some changes.

Regeneron Soars After Eye Drug Competitor Novartis Releases Positive Data

Regeneron Soars After Eye Drug Competitor Novartis Releases Positive Data

Novartis released data from its RTH258 clinical trials illustrating that RTH258 does not need to be injected as often as Regeneron's rival drug, Eylea.

Novartis Secures European Approval For Biosimilar Cancer Treatment Rixathon

Novartis Secures European Approval For Biosimilar Cancer Treatment Rixathon

Novartis said Monday that it has received EC approval for a blood cancer treatment known as Rixathon, a biosimilar version of Roche's Rituxan that generated $7.5 billion in 2016 sales.

Google and Novartis Back Medicxi's New $300 Million Fund

Google and Novartis Back Medicxi's New $300 Million Fund

Developing a promising drug? This new investment fund is looking to invest in Phase 2 candidates.

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..

The Reasons Kite Pharma Is Set to Fly Higher

The Reasons Kite Pharma Is Set to Fly Higher

BTIG analyst Dane Leone noted three key reasons why he executed today's upgrade of the stock.

Bristol Myers, Novartis to Explore Potential Treatment for Metastatic Colorectal Cancer

Bristol Myers, Novartis to Explore Potential Treatment for Metastatic Colorectal Cancer

Bristol-Myers will conduct the study and both companies will evaluate the findings.

Bluebird Bio Is Liked by Analysts, Cognizant Isn't

Bluebird Bio Is Liked by Analysts, Cognizant Isn't

Here are Tuesday's top research calls, including upgrades for Bluebird Bio and Tenet Healthcare, a downgrade for Cognizant and new coverage of Hormel.

Why I'm Positive on Novartis

Why I'm Positive on Novartis

Here's where to buy NVS.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ENLC, NVS, RDI Downgrades: ATAI, PFSI, TICC, WMIH Initiations: GMRE, NGVT Read on to get TheStreet Quant Ratings' detailed report:

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

Rivals Kite Pharma and Novartis are still out in front, but updated efficacy and safety data from Juno's JCAR017 program in patients with aggressive non-Hodgkin's lymphoma are very competitive.

Biotech Movers: Minerva, XBiotech, Aduro

Biotech Movers: Minerva, XBiotech, Aduro

Minerva Neurosciences, XBiotech and Aduro Biotech were among the biotech movers in premarket trading on Thursday.

Novartis Cautions on U.S. Pricing Pressures; Shares Edge Higher on Steady Outlook for Sandoz Sales

Novartis Cautions on U.S. Pricing Pressures; Shares Edge Higher on Steady Outlook for Sandoz Sales

Novartis shares edged higher after the Swiss drugmaker cautioned that pricing pressures in the U.S. and the delay of a multiple sclerosis therapy dosage would hit its generic division's sales.

Bristol-Myers Hookup Boosts Array BioPharma

Bristol-Myers Hookup Boosts Array BioPharma

Arrary reacquired MEK inhibitor in 2015 as part of FTC settlement with Novartis.

S&P 500, Nasdaq Edge Higher as Crude Rebounds From Thursday Slump

S&P 500, Nasdaq Edge Higher as Crude Rebounds From Thursday Slump

Stocks are narrowly mixed on Friday, putting the S&P 500 and Nasdaq at risk of snapping a six-day winning streak.

Perrigo, Taro Show Perils of Failure to Branch in Branded Drugs

Perrigo, Taro Show Perils of Failure to Branch in Branded Drugs

The latest earnings from two of the largest generic drug makers show how important it is for generic firms to have their own stable of higher-margin branded products.

Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting

Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting

The drug companies engineering T-cells to recognize and kill cancer, otherwise known as chimeric antigen receptor T-cells, or CAR-Ts, will be busy at the ASCO annual meeting in June.

Aduro Biotech, Merck Team on Cancer Drug Trial

Aduro Biotech, Merck Team on Cancer Drug Trial

Aduro Biotech and Merck will team on two separate trials featuring Aduro's CRS-207 and Merck's Keytruda to explore treatments for mesothelioma and gastric cancer.

GlaxoSmithKline Could Buy Out Partner Novartis

GlaxoSmithKline Could Buy Out Partner Novartis

Novartis holds a 36.5% stake in the healthcare company.

Allergan Must Show Mergers, Drug Pipeline Can Make Up For Lost Sales

Allergan Must Show Mergers, Drug Pipeline Can Make Up For Lost Sales

Analysts estimate total revenue will fall 6.9% to $3.53 billion in the quarter due to the loss of patent exclusivity on some drugs and divestitures of major business lines.

How Far Into the Drug Pipeline Should the FTC Reach?

How Far Into the Drug Pipeline Should the FTC Reach?

Novartis exec argues the FTC should keep its hands off when pharmaceutical products are in early stages of development.

Surveying the NASH Drug Landscape

Surveying the NASH Drug Landscape

Biotech investors should keep a close eye on the progress in this huge potential market.

Nasdaq Tops 6,000 in Busy Day of Milestones for Wall Street

Nasdaq Tops 6,000 in Busy Day of Milestones for Wall Street

Another big rally made for a day of milestones: the Dow and S&P 500 enjoyed their best back-to-back gains of the year, while the Nasdaq scored a new record.

Novartis, Amgen Divvy Global Marketing of New Migraine Drug

Novartis, Amgen Divvy Global Marketing of New Migraine Drug

Estimates for erenumab annual sales run as high as $2.3 billion.

Stocks Hold at Highs as Dow, S&P 500 Enjoy Best Two-Day Stretch of 2017

Stocks Hold at Highs as Dow, S&P 500 Enjoy Best Two-Day Stretch of 2017

Better-than-expected earnings from industry leaders including Caterpillar and McDonald's push the Dow to log triple-digit gains for the second day in a row, its best two-day stretch of the year.

Caterpillar Hauls Dow Sharply Higher, Nasdaq Tops 6,000 for First Time

Caterpillar Hauls Dow Sharply Higher, Nasdaq Tops 6,000 for First Time

A stream of positive earnings reports keep stocks on the rise on Tuesday with the Dow Jones Industrial Average logging triple-digit gains for the second day in a row.

Stock Futures See More Gains on a Stream of Positive Earnings

Stock Futures See More Gains on a Stream of Positive Earnings

Stock futures move higher on Tuesday, extending gains seen a day earlier, after a series of positive earnings results from the likes of DuPont, Novartis, and Rite Aid.

Novartis Shares Jump After Group Holds To Full Year Forecasts; Sees Entresto Growth

Novartis Shares Jump After Group Holds To Full Year Forecasts; Sees Entresto Growth

Novartis shares led gainers in Zurich Tuesday after the pharmaceuticals group held on to full year earnings targets and narrowly beast analysts' forecasts for first quarter earnings.

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.

Weekly Roundup

Earnings and hopes for a tax plan help lift the markets. Portfolio moves include exiting a utility position.

TheStreet Quant Rating: A- (Buy)